Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer

Creators: Giunta, Emilio Francesco; Signori, Alessio; West, Howard Jack; Metro, Giulio; Friedlaender, Alex; Parikh, Kaushal; Banna, Giuseppe Luigi; Addeo, Alfredo

Others:: Giunta, Emilio Francesco; Signori, Alessio; West, Howard Jack; Metro, Giulio; Friedlaender, Alex; Parikh, Kaushal; Banna, Giuseppe Luigi; Addeo, Alfredo

Description

Second and third-generation ALK inhibitors (ALKIs) have been recently approved for ALK-translocated lung cancer treatment, improving - and expanding - the first-line scenario.

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer

Description

Additional details